ALK and non-small cell lung carcinoma: In the randomized phase 3 ALESIA study (NCT02838420), treatment-naïve Asian patients with advanced ALK-positive NSCLC were enrolled to receive the globally approved 600 mg twice-daily alectinib dose; the primary objective was to assess whether the PFS benefit of alectinib in this patient population was consistent with that observed in the global ALEX study.